Member Info for mdle4

Hi - brought in last month, like the Academy and the teams they are building, plus the sponsorship deals, all looks very promising and you can still buy below the IPO price (at the moment).

great thank you for the information

Hi could someone advise me on the best broker to buy these through as Halifax don't deal with AQUIS Exchange -

https://www.youtube.com/watch?v=3iWYZcRwWi8

Maybe of interest as IMM hold a stake in this....13.37%

Yes, you heard correctly, great presentation as usual, little bit of patience required let CF and the team do their work and like him being a shareholder the rewards will come. GLA

Mine popped up in my Halifax account late yesterday

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM). Malik examines the company's flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.

ImmuPharma recently updated the market on progress within its lupus drug, Lupuzor, following guidance from the FDA as part of a Type A meeting with its licensing partner Avion Pharmaceuticals As part of the FDA feedback, Avion and ImmuPharma will develop and validate a bioanalytical assay in order to confirm the unique pharmacokinetic profile of Lupuzor™, known as a PK study.

For the investment case, Malik says with a strong data file ImmuPharma has shared with Avion they be enriching the patient group for the Phase III trial, targeting the most responsive lupus patients, from data taken from the first Phase III trial. With a clear roadmap which paves the way to start the Phase III trial in H2 2021.

The strengthened balance sheet position following the £6.5m placing in September 2020, provides a cash runway to end 2023. Lupus being an attractive market and poorly met medical need, Malik believes the shares are oversold and reiterate their BUY rating and TP of 100p.

Halifax Share Dealing & Stocks & Shares ISA accounts lets you trade with six global stock markets through them:

New York (NYSE, NASDAQ, NYSEAmex)
Frankfurt (XETRA)
Milan (MTA)
Paris (Euronext)
Amsterdam (Euronext)
Brussels (Euronext)

third facility to be announced by end of Jan 21, quite a number of wearable deals due were CF words, he has never been more excited about how things are going to progress (or words of that effect), great presentation - he mentioned SP and basically said that will take care of its self (30-50% every six months) - be relaxed were his words.

‘past posts on hear’ sorry typo should be ‘past posts on here’!!

No problem I knew what you meant, no apology needed, hopefully the market is turning and are now understanding this is NOT a Covid stock but a world leader in testing and pharmaceutical services company, all document in past posts on hear and always covered by CF in his presentations. I wish all holders the best of luck - the future looks more than interesting.

10% of business is Covid related, 90% is NOT.

Do you have a shareholder list showing OO on it please?.

Be nice just to get off the launch pad! come on NFX .

https://www.newstalk.com/podcasts/highlights-from-the-hard-shoulder/irish-businesses-benefiting-pandemic

there was a system problem and all share prices showed trades as 13 Feb, since been solved but guess this will stay showing this until suspension lifted.

Just been watching BBC News Channel - repeated the news from earlier showing the clinic and a room which will be used in the human trials. Good interview with Andrew Catchpole, Hvivo’s chief scientist.

www.morningstar.co.uk/uk/news/AN_1572002833886516300/nuformix-confirms-japan-asia-licencing-talks-as-shares-surge.aspx

I have a very small free float here as I took out my initial investment & a bit more just before the results from phase 3 were announced, my own opinion on where we are is the following:1. Was concerned when we put 2 million into Tim's other company especially as this has never been mentioned since in any company update, although this could be a good investment if they ever float and can get their portfolio moving.2. Lanstead, any company is out to make money so surely they are not that naïve to throw money at Imm without having some sort of idea on what the plan is going forward. Its not like before with the other money raise at £1.44 just before results as you could have taken this as insurance from Imm that if the results were not great they would have funds to continue so the risk then was much greater for anyone investing. My point is Tim stated in the last video financials were very strong so this investment I believe is different in that is was not a fund raise made by Imm but Lanstead wanting to make the investment, I could be wrong of course as no expert.3. Extended trail results - who knows, the argument is always the same the later the announcement people start to assume the worse, but sometimes this is not the case. I have an open mind on the results but have a slight hunch they will be favourable.I wish everyone invested here the best of luck and of course any positive outcome more importantly will improve the lives of many, many people.(something we should all not forget).

https://eberstech.com/